Open Access

STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells

  • Authors:
    • Li Lin
    • David Jou
    • Yina Wang
    • Haiyan Ma
    • Tianshu Liu
    • James Fuchs
    • Pui-Kai Li
    • Jiagao Lü
    • Chenglong Li
    • Jiayuh Lin
  • View Affiliations

  • Published online on: October 12, 2016     https://doi.org/10.3892/ijo.2016.3728
  • Pages: 2265-2274
  • Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Persistent activation of signal transducers and activators of transcription 3 (STAT3) is commonly detected in many types of cancer including pancreatic cancer. Whether STAT3 is activated in stem cell-like pancreatic cancer cells and the effect of STAT3 inhibition, is still unknown. Flow cytometry was used to isolate pancreatic cancer stem-like cells which are identified by both aldehyde dehydrogenase (ALDH)-positive (ALDH+) as well as cluster of differentiation (CD) 44-positive/CD24-positive subpopulations (CD44+/CD24+). STAT3 activation and the effects of STAT3 inhibition by STAT3 inhibitors, LLL12, FLLL32, and Stattic in ALDH+ and CD44+/CD24+ cells were examined. Our results showed that ALDH+ and CD44+/CD24+ pancreatic cancer stem-like cells expressed higher levels of phosphorylated STAT3, an active form of STAT3, compared to ALDH-negative (ALDH-) and CD44-negative/CD24-negative (CD44-/CD24-) pancreatic cancer cells, suggesting that STAT3 is activated in pancreatic cancer stem-like cells. Small molecular STAT3 inhibitors inhibited STAT3 phosphorylation, STAT3 downstream target gene expression, cell viability, and tumorsphere formation in ALDH+ and CD44+/CD24+ cells. Our results indicate that STAT3 is a novel therapeutic target in pancreatic cancer stem-like cells and inhibition of activated STAT3 in these cells by STAT3 inhibitors may offer an effective treatment for pancreatic cancer.
View Figures
View References

Related Articles

Journal Cover

November 2016
Volume 49 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Lin, L., Jou, D., Wang, Y., Ma, H., Liu, T., Fuchs, J. ... Lin, J. (2016). STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells. International Journal of Oncology, 49, 2265-2274. https://doi.org/10.3892/ijo.2016.3728
MLA
Lin, L., Jou, D., Wang, Y., Ma, H., Liu, T., Fuchs, J., Li, P., Lü, J., Li, C., Lin, J."STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells". International Journal of Oncology 49.6 (2016): 2265-2274.
Chicago
Lin, L., Jou, D., Wang, Y., Ma, H., Liu, T., Fuchs, J., Li, P., Lü, J., Li, C., Lin, J."STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells". International Journal of Oncology 49, no. 6 (2016): 2265-2274. https://doi.org/10.3892/ijo.2016.3728